BR112021002692A2 - uso de comprimidos desintegrantes orais de riluzol para o tratamento de doenças - Google Patents
uso de comprimidos desintegrantes orais de riluzol para o tratamento de doenças Download PDFInfo
- Publication number
- BR112021002692A2 BR112021002692A2 BR112021002692-4A BR112021002692A BR112021002692A2 BR 112021002692 A2 BR112021002692 A2 BR 112021002692A2 BR 112021002692 A BR112021002692 A BR 112021002692A BR 112021002692 A2 BR112021002692 A2 BR 112021002692A2
- Authority
- BR
- Brazil
- Prior art keywords
- bhv
- riluzole
- pbo
- patient
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| US62/764,864 | 2018-08-16 | ||
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021002692A2 true BR112021002692A2 (pt) | 2021-05-11 |
Family
ID=69525906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021002692-4A BR112021002692A2 (pt) | 2018-08-16 | 2019-08-15 | uso de comprimidos desintegrantes orais de riluzol para o tratamento de doenças |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210315865A1 (https=) |
| EP (1) | EP3836922B1 (https=) |
| JP (2) | JP2021534160A (https=) |
| KR (1) | KR20210045423A (https=) |
| CN (1) | CN112584831A (https=) |
| AU (1) | AU2019322889A1 (https=) |
| BR (1) | BR112021002692A2 (https=) |
| CA (1) | CA3109769A1 (https=) |
| EA (1) | EA202190544A1 (https=) |
| ES (1) | ES2987802T3 (https=) |
| IL (1) | IL280657A (https=) |
| MX (2) | MX2021001563A (https=) |
| PH (1) | PH12021550218A1 (https=) |
| SG (1) | SG11202100880VA (https=) |
| WO (1) | WO2020037152A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805969B2 (ja) * | 2020-06-24 | 2026-01-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
| US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| WO2022103639A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| WO2004047793A1 (en) * | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| ES2564187T3 (es) * | 2005-04-05 | 2016-03-18 | Yale University | Agentes de modulación de glutamato en el tratamiento de trastornos mentales |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| CN107735077A (zh) * | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
| WO2016081472A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
| KR102462638B1 (ko) * | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2016140879A1 (en) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
-
2019
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 EP EP19849456.9A patent/EP3836922B1/en active Active
- 2019-08-15 CA CA3109769A patent/CA3109769A1/en active Pending
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en not_active Abandoned
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en not_active Ceased
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko not_active Ceased
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt not_active Application Discontinuation
- 2019-08-15 ES ES19849456T patent/ES2987802T3/es active Active
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
- 2021-02-08 MX MX2024007642A patent/MX2024007642A/es unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019322889A1 (en) | 2021-03-04 |
| EP3836922A1 (en) | 2021-06-23 |
| JP2021534160A (ja) | 2021-12-09 |
| CA3109769A1 (en) | 2020-02-20 |
| WO2020037152A1 (en) | 2020-02-20 |
| EP3836922A4 (en) | 2022-05-04 |
| EP3836922C0 (en) | 2024-08-07 |
| US20210315865A1 (en) | 2021-10-14 |
| ES2987802T3 (es) | 2024-11-18 |
| IL280657A (en) | 2021-03-25 |
| MX2021001563A (es) | 2021-06-15 |
| CN112584831A (zh) | 2021-03-30 |
| MX2024007642A (es) | 2024-07-04 |
| SG11202100880VA (en) | 2021-02-25 |
| KR20210045423A (ko) | 2021-04-26 |
| EP3836922B1 (en) | 2024-08-07 |
| EA202190544A1 (ru) | 2021-06-18 |
| JP2024010017A (ja) | 2024-01-23 |
| PH12021550218A1 (en) | 2021-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021002692A2 (pt) | uso de comprimidos desintegrantes orais de riluzol para o tratamento de doenças | |
| CN108883108B (zh) | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 | |
| US20160166543A1 (en) | Stable combination oral liquid formulation of melatonin and an antihistaminic agent | |
| US20260014123A1 (en) | Use of riluzole oral disintegrating tablets for treating diseases | |
| AU2018364749B2 (en) | Use of riluzole prodrugs to treat ataxias | |
| BR112017010423B1 (pt) | Formulação sublingual de riluzol e uso da mesma | |
| WO2023186827A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| Benzer et al. | Case 40-2013: a 36-year-old man with agitation and paranoia | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| BR112020011345A2 (pt) | tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas | |
| WO2024160392A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| BR112021000768A2 (pt) | uso de pró-medicamentos de riluzol para tratar a doença de alzheimer | |
| Takahashi et al. | Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats | |
| Vrolijk et al. | Haemodynamic effects of the flavonoid quercetin in rats revisited | |
| Kleindienst et al. | Efect of dimethyl sulfoxide on blood—-brain barrier integrity following middle cerebral artery OC--clusion in the rat | |
| EA046859B1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| JP2010163426A (ja) | ホスホジエステラーゼ５阻害剤とアルギニンを含有する医薬組成物 | |
| JP2019524782A (ja) | Ｎ，ｎ−ビス−２−メルカプトエチルイソフタルアミドの新規用途 | |
| Koshy et al. | Thiopentone–midazolam mixture as an induction agent for general anasthesia on ‘in-patients’ | |
| Brenner et al. | A pyridoxine-dependent behavioral disorder unmasked by isoniazid | |
| KR20050031499A (ko) | 뇌허혈성 질환의 예방 및 치료용 조성물 | |
| AU2023242438A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| ES2349535T3 (es) | Método de tratamiento de un trastorno de ansiedad. | |
| CN119546294A (zh) | 使用CNS渗透性sGC刺激剂治疗线粒体疾病Zagociguat | |
| HK40033906A (en) | Use of riluzole prodrugs to treat ataxias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |